Estrella Immunopharma (ESLA) risk factors, FY2025 10-K

Risks Related to Estrella’s Operating History and Financial Condition

1. 01We are a clinical stage biotechnology company with a history of losses. We expect to continue to incur significant losses for the foreseeable future and may never achieve or maintain profitability37% rewritten
2. 02We will need substantial additional funds to advance development of product candidates, and we cannot guarantee that we will have sufficient funds available in the future to develop and commercialize our current or potential future product candidates and technologies
3. 03Members of our management team have limited experience in managing the day-to-day operations of a public company and, as a result, we may incur additional expenses associated with the management of our company40% rewritten

Risks Related to the Development and Clinical Testing of Our Product Candidates

1. 04Our current product candidates are in either preclinical or clinical development. One or all of our current product candidates may fail in clinical development or suffer delays that materially and adversely affect their commercial viability100% rewritten
2. 05Our ability to achieve and sustain profitability depends on obtaining regulatory approvals for and successfully commercializing product candidates, either with Eureka pursuant to the Services Agreement or with other collaboratorsNew
3. 06We may not be successful in our efforts to use and expand our use of the ARTEMIS ® platform to expand our pipeline of product candidates
4. 07While our IND for EB103 was cleared by the FDA on March 2, 2023 and we believe our pipeline will yield additional INDs, we may not be able to file additional INDs to commence clinical trials on the timelines we expect, and even if we are able to, the FDA may not permit us to proceed94% rewritten
5. 08We and our collaborators may not achieve projected discovery and development milestones and other anticipated key events in the time frames that we or they announce, which could have an adverse impact on our business and could cause our stock price to decline
6. 09Clinical trials are expensive, time-consuming, and difficult to design and implement
7. 10If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected
8. 11If clinical trials for our product candidates are prolonged, delayed, or stopped, we may be unable to seek or obtain regulatory approval and commercialize our product candidates on a timely basis, or at all, which would require us to incur additional costs and delay our receipt of any product revenue
9. 12If we decide to seek orphan drug designation for one or more of our product candidates, we may be unsuccessful or may be unable to maintain the benefits associated with orphan drug designation for our current or future product candidates that we may develop
10. 13We may not be able to conduct, or contract with others to conduct, animal testing in the future, which could harm our research and development activities

Risks Related to Third Parties

1. 14We rely on third parties to conduct our preclinical studies and our clinical trial for EB103, and plan to rely on third parties to conduct any clinical trials for our other product candidates, and those third parties may not perform satisfactorily
2. 15As a result, we may not be able to conduct these collaborations in the manner or on the time schedule we previously contemplated, which may negatively impact our business operations
3. 16We may not realize the anticipated benefits of our prior collaboration agreement with Imugene28% rewritten
4. 17Changes in methods of product candidate manufacturing or formulation may result in the need to perform new clinical trials, which would require additional costs and cause delay

Risks Related to Our Business and Operations

1. 18If the market opportunities for our current and potential future product candidates, are smaller than we believe they are, our future product revenues may be adversely affected, and our business may suffer80% rewritten
2. 19AI systems, if not adequately secured, could expose our company to cybersecurity threats, including data breaches, intellectual property theft, and system compromises. The exploitation of such vulnerabilities could lead to reputational damage, legal liabilities, and regulatory penaltiesNew
3. 20Any inability to attract and retain qualified key management, technical personnel and employees would impair our ability to implement our business plan
4. 21As our current and potential future product candidates enter and advance through preclinical studies and any clinical trials, we will need to expand our development, regulatory, and manufacturing capabilities or contract with other organizations to provide these capabilities for us
5. 22Public opinion and scrutiny of immunotherapy approaches may impact public perception of Estrella and product candidates, or may adversely affect our ability to conduct our business and our business plans
6. 23Our potential future international operations may expose us to business, political, operational, and financial risks associated with doing business outside of the United States
7. 24Our business entails a significant risk of product liability, and our inability to obtain sufficient insurance coverage could have a material adverse effect on our business, financial condition, results of operations and prospects
8. 25Our employees, principal investigators, consultants, and commercial collaborators may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements26% rewritten
9. 26If we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected74% rewritten
10. 27Our business, operations, financial position and clinical development plans and timelines could be materially adversely affected by the continuing military action in Ukraine, the war between Israel and Hamas, and the armed conflict between the United States/Israel and Iran35% rewritten
11. 28Inflation and higher interest rates could increase our operating costs and adversely affect our liquidity and ability to raise capitalNew

Risks Related to the Separation and Our Relationship with Eureka

1. 29We will incur incremental costs as a standalone public company
2. 30Certain of our officers or directors may have actual or potential conflicts of interest because of their equity interests in or positions with Eureka
3. 31We rely on Eureka for our research and development efforts

Risks Related to Our Intellectual Property

1. 32Our licenses and other material contracts may be invalid, unenforceable, or limited as to intellectual property and/or may impede, limit, or eliminate our ability to secure or protect our intellectual property, including in-licensed patent rights and any future developments
2. 33The patent protection and patent prosecution for some of our product candidates and technologies may be dependent on third parties
3. 34We may be unable to acquire or in-license any relevant third-party intellectual property rights that we identify as necessary or important to our business operations23% rewritten
4. 35Therefore, even if we successfully develop and commercialize products, we may be unable to achieve or maintain profitabilityNew
5. 36Patent terms may not be able to protect our competitive position for an adequate period of time with respect to our current or future technologies or product candidates
6. 37Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our current or any future technologies or product candidates
7. 38We or our licensors may be subject to lawsuits or litigation to protect or enforce our in-licensed patents or other intellectual property, which could result in substantial costs and liability and prevent us from commercializing our potential products
8. 39We may not be able to protect our intellectual property rights throughout the world, which could negatively impact our business
9. 40Intellectual property litigation may lead to unfavorable publicity that harms our reputation and causes the market price of our Common Stock to decline
10. 41If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed
11. 42We may be subject to claims that we or our employees or consultants have wrongfully used or disclosed alleged trade secrets or other proprietary information of third parties, including our employees’ or consultants’ former employers or their clients
12. 43Our licensors or we may be subject to claims challenging the inventorship of our in-licensed patents and other intellectual property
13. 44Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by government patent agencies, and our licensors’ patent protection could be reduced or eliminated for non-compliance with these requirements
14. 45If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected
15. 46Intellectual property rights do not necessarily address all potential threats to our business
16. 47If any negative data were to arise with respect to the use of our licensed technology in territories where such technology is licensed to a third party, it could negatively affect our ability to develop our product candidates in territories where we license such technology

Risks Related to Government Regulation

1. 48Clinical development includes a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results
2. 49Furthermore, we expect to rely on our CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials and, while we expect to enter into agreements governing their committed activities, we have limited influence over their actual performance
3. 50We may be unable to obtain U.S. or foreign regulatory approval and, as a result, be unable to commercialize our current or potential future product candidates
4. 51Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions
5. 52The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenue
6. 53Any product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated
7. 54Healthcare legislative reform measures may have a material adverse effect on our business and results of operations93% rewritten
8. 55Failure to comply with health and data protection laws and regulations could lead to government enforcement actions (which could include civil or criminal penalties), private litigation or adverse publicity and could negatively affect our operating results and business35% rewritten
9. 56If we or our existing or potential future collaborators, manufacturers or service providers fail to comply with healthcare laws and regulations, we or they could be subject to enforcement actions, which could affect our ability to develop, market and sell our product candidates and may harm our reputation
10. 57If we fail to comply with U.S. and foreign regulatory requirements, regulatory authorities could limit or withdraw any marketing or commercialization approvals we may receive and subject us to other penalties that could materially harm our business
11. 58Even if we are able to commercialize any product candidate, such product candidate may become subject to unfavorable pricing regulations or third-party coverage and reimbursement policies, which would harm our business
12. 59We are subject to U.S. and foreign anti-corruption and anti-money laundering laws with respect to our operations and non-compliance with such laws can subject us to criminal or civil liability and harm our business63% rewritten
13. 60We or the related parties upon whom we depend may be adversely affected by natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster
14. 61Our quarterly operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline
15. 62We may be subject to claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties
16. 63Our management team is not subject to non-competition restrictions if they terminate their employment with us

Risks Related to our Securities

1. 64Our Common Stock price may be volatile40% rewritten
2. 65If we fail to maintain compliance with Nasdaq listing standards, our Common Stock could be delisted, which could adversely affect the trading price and liquidity of our Common Stock and subject us to additional trading restrictions, including the “penny stock” rulesNew
3. 66Estrella may incur significant costs from class action litigation due to the expected stock volatility87% rewritten
4. 67We are a “controlled company” within the meaning of Nasdaq listing rules and, as a result, can rely on exemptions from certain corporate governance requirements that provide protection to shareholders of other companies
5. 68Estrella is an “emerging growth company” and it cannot be certain if the reduced disclosure requirements applicable to emerging growth companies will make our Common Stock less attractive to investors and may make it more difficult to compare performance with other public companies
6. 69Future sales and issuances of Common Stock or rights to purchase Common Stock could result in additional dilution of the percentage ownership of Estrella stockholders and could cause the price of our Common Stock to fall58% rewritten
7. 70Estrella’s internal control over financial reporting may not prevent or detect all errors or acts of fraud
8. 71Estrella has identified material weaknesses in its internal control over financial reporting which, if not corrected, could affect the reliability of Estrella’s consolidated financial statements, and have other adverse consequences39% rewritten
9. 72The identified material weaknesses, if not corrected, could result in a material misstatement to Estrella’s consolidated financial statements that may not be prevented or detected30% rewritten
10. 73Reports published by analysts, including projections in those reports that differ from Estrella’s actual results, could adversely affect the price and trading volume of our Common Stock
11. 74The obligations associated with being a public company will involve significant expenses and will require significant resources and management attention, which may divert from Estrella’s business operations
12. 75These provisions, alone or together, could delay or prevent hostile takeovers and changes in control or changes in our management. These provisions could also limit the price that investors might be willing to pay in the future for shares of our Common Stock, thereby depressing the market price of our Common Stock